X4-logo.png
X4 Pharmaceuticals to Participate in Upcoming Investor Conferences
September 15, 2021 16:05 ET | X4 Pharmaceuticals
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
X4-logo.png
X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer
September 08, 2021 08:00 ET | X4 Pharmaceuticals
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
X4-logo.png
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2021 16:01 ET | X4 Pharmaceuticals
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4-logo.png
X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 01, 2021 08:00 ET | X4 Pharmaceuticals
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
X4-logo.png
X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference
August 04, 2021 16:01 ET | X4 Pharmaceuticals
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from...
X4-logo.png
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results
August 03, 2021 08:00 ET | X4 Pharmaceuticals
Twenty-three patients now enrolled in ongoing pivotal Phase 3 trial in WHIM syndrome, surpassing minimum needed for primary endpoint analyses; enrollment to complete in 3Q21 with top-line data...
X4-logo.png
X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021
July 22, 2021 16:05 ET | X4 Pharmaceuticals
BOSTON, July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4-logo.png
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2021 16:01 ET | X4 Pharmaceuticals
BOSTON, July 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
X4-logo.png
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
June 11, 2021 03:00 ET | X4 Pharmaceuticals
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin...
X4-logo.png
X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia
May 26, 2021 08:00 ET | X4 Pharmaceuticals
Poster presentation by lead author Dr. Steven Treon available on the EHA website Friday, June 11, 2021 at 9:00 am CET/3:00 am ET Conference call and webcast with poster co-author Dr. Christian Buske...